1.ROS Scavenger, Ebselen, Has No Preventive Effect in New Hearing Loss Model Using a Cholesterol-Chelating Agent
Min Young LEE ; Lisa L KABARA ; Donald L SWIDERSKI ; Yehoash RAPHAEL ; R Keith DUNCAN ; Young Ho KIM
Journal of Audiology & Otology 2019;23(2):69-75
BACKGROUND AND OBJECTIVES: The antioxidant ebselen will be able to limit or prevent the ototoxicity arising from 2-hydroxypropyl-β-cyclodextrin (HPβCD). Niemann-Pick Type C (NPC) disease is a disorder of lysosomal storage manifested in sphingolipidosis. Recently, it was noted that experimental use of HPβCD could partially resolve the symptoms in both animals and human patients. Despite its desirable effect, HPβCD can induce hearing loss, which is the only major side effect noted to date. Understanding of the pathophysiology of hearing impairment after administration of HPβCD and further development of preventive methods are essential to reduce the ototoxic side effect. The mechanisms of HPβCD-induced ototoxicity remain unknown, but the resulting pathology bears some resemblance to other ototoxic agents, which involves oxidative stress pathways. To indirectly determine the involvement of oxidative stress in HPβCD-induced ototoxicity, we tested the efficacy of an antioxidant reagent, ebselen, on the extent of inner ear side effects caused by HPβCD. MATERIALS AND METHODS: Ebselen was applied prior to administration of HPβCD in mice. Auditory brainstem response thresholds and otopathology were assessed one week later. Bilateral effects of the drug treatments also were examined. RESULTS: HPβCD-alone resulted in bilateral, severe, and selective loss of outer hair cells from base to apex with an abrupt transition between lesions and intact areas. Ebselen co-treatment did not ameliorate HPβCD-induced hearing loss or alter the resulting histopathology. CONCLUSIONS: The results indirectly suggest that cochlear damage by HPβCD is unrelated to reactive oxygen species formation. However, further research into the mechanism(s) of HPβCD otopathology is necessary.
Animals
;
Ear, Inner
;
Evoked Potentials, Auditory, Brain Stem
;
Hair Cells, Auditory, Outer
;
Hearing Loss
;
Hearing
;
Humans
;
Mice
;
Oxidative Stress
;
Pathology
;
Reactive Oxygen Species
;
Sphingolipidoses
;
Tight Junctions
2.Do some patients receive unnecessary parenteral nutrition after pancreatoduodenectomy?Results from an international multicentre study
Thomas B. RUSSELL ; Peter L. LABIB ; Paula MURPHY ; Fabio AUSANIA ; Elizabeth PANDO ; Keith J. ROBERTS ; Ambareen KAUSAR ; Vasileios K. MAVROEIDIS ; Gabriele MARANGONI ; Sarah C. THOMASSET ; Adam E. FRAMPTON ; Pavlos LYKOUDIS ; Manuel MAGLIONE ; Nassir ALHABOOB ; Hassaan BARI ; Andrew M. SMITH ; Duncan SPALDING ; Parthi SRINIVASAN ; Brian R. DAVIDSON ; Ricky H. BHOGAL ; Daniel CROAGH ; Ismael DOMINGUEZ ; Rohan THAKKAR ; Dhanny GOMEZ ; Michael A. SILVA ; Pierfrancesco LAPOLLA ; Andrea MINGOLI ; Alberto PORCU ; Nehal S. SHAH ; Zaed Z. R. HAMADY ; Bilal AL-SARRIEH ; Alejandro SERRABLO ; ; Somaiah AROORI
Annals of Hepato-Biliary-Pancreatic Surgery 2024;28(1):70-79
Background:
s/Aims: After pancreatoduodenectomy (PD), an early oral diet is recommended; however, the postoperative nutritional management of PD patients is known to be highly variable, with some centers still routinely providing parenteral nutrition (PN). Some patients who receive PN experience clinically significant complications, underscoring its judicious use. Using a large cohort, this study aimed to determine the proportion of PD patients who received postoperative nutritional support (NS), describe the nature of this support, and investigate whether receiving PN correlated with adverse perioperative outcomes.
Methods:
Data were extracted from the Recurrence After Whipple’s study, a retrospective multicenter study of PD outcomes.
Results:
In total, 1,323 patients (89%) had data on their postoperative NS status available. Of these, 45% received postoperative NS, which was “enteral only,” “parenteral only,” and “enteral and parenteral” in 44%, 35%, and 21% of cases, respectively. Body mass index < 18.5 kg/m2 (p = 0.03), absence of preoperative biliary stenting (p = 0.009), and serum albumin < 36 g/L (p = 0.009) all correlated with receiving postoperative NS. Among those who did not develop a serious postoperative complication, i.e., those who had a relatively uneventful recovery, 20% received PN.
Conclusions
A considerable number of patients who had an uneventful recovery received PN. PN is not without risk, and should be reserved for those who are unable to take an oral diet. PD patients should undergo pre- and postoperative assessment by nutrition professionals to ensure they are managed appropriately, and to optimize perioperative outcomes.
3.Do some patients receive unnecessary parenteral nutrition after pancreatoduodenectomy?Results from an international multicentre study
Thomas B. RUSSELL ; Peter L. LABIB ; Paula MURPHY ; Fabio AUSANIA ; Elizabeth PANDO ; Keith J. ROBERTS ; Ambareen KAUSAR ; Vasileios K. MAVROEIDIS ; Gabriele MARANGONI ; Sarah C. THOMASSET ; Adam E. FRAMPTON ; Pavlos LYKOUDIS ; Manuel MAGLIONE ; Nassir ALHABOOB ; Hassaan BARI ; Andrew M. SMITH ; Duncan SPALDING ; Parthi SRINIVASAN ; Brian R. DAVIDSON ; Ricky H. BHOGAL ; Daniel CROAGH ; Ismael DOMINGUEZ ; Rohan THAKKAR ; Dhanny GOMEZ ; Michael A. SILVA ; Pierfrancesco LAPOLLA ; Andrea MINGOLI ; Alberto PORCU ; Nehal S. SHAH ; Zaed Z. R. HAMADY ; Bilal AL-SARRIEH ; Alejandro SERRABLO ; ; Somaiah AROORI
Annals of Hepato-Biliary-Pancreatic Surgery 2024;28(1):70-79
Background:
s/Aims: After pancreatoduodenectomy (PD), an early oral diet is recommended; however, the postoperative nutritional management of PD patients is known to be highly variable, with some centers still routinely providing parenteral nutrition (PN). Some patients who receive PN experience clinically significant complications, underscoring its judicious use. Using a large cohort, this study aimed to determine the proportion of PD patients who received postoperative nutritional support (NS), describe the nature of this support, and investigate whether receiving PN correlated with adverse perioperative outcomes.
Methods:
Data were extracted from the Recurrence After Whipple’s study, a retrospective multicenter study of PD outcomes.
Results:
In total, 1,323 patients (89%) had data on their postoperative NS status available. Of these, 45% received postoperative NS, which was “enteral only,” “parenteral only,” and “enteral and parenteral” in 44%, 35%, and 21% of cases, respectively. Body mass index < 18.5 kg/m2 (p = 0.03), absence of preoperative biliary stenting (p = 0.009), and serum albumin < 36 g/L (p = 0.009) all correlated with receiving postoperative NS. Among those who did not develop a serious postoperative complication, i.e., those who had a relatively uneventful recovery, 20% received PN.
Conclusions
A considerable number of patients who had an uneventful recovery received PN. PN is not without risk, and should be reserved for those who are unable to take an oral diet. PD patients should undergo pre- and postoperative assessment by nutrition professionals to ensure they are managed appropriately, and to optimize perioperative outcomes.
4.Do some patients receive unnecessary parenteral nutrition after pancreatoduodenectomy?Results from an international multicentre study
Thomas B. RUSSELL ; Peter L. LABIB ; Paula MURPHY ; Fabio AUSANIA ; Elizabeth PANDO ; Keith J. ROBERTS ; Ambareen KAUSAR ; Vasileios K. MAVROEIDIS ; Gabriele MARANGONI ; Sarah C. THOMASSET ; Adam E. FRAMPTON ; Pavlos LYKOUDIS ; Manuel MAGLIONE ; Nassir ALHABOOB ; Hassaan BARI ; Andrew M. SMITH ; Duncan SPALDING ; Parthi SRINIVASAN ; Brian R. DAVIDSON ; Ricky H. BHOGAL ; Daniel CROAGH ; Ismael DOMINGUEZ ; Rohan THAKKAR ; Dhanny GOMEZ ; Michael A. SILVA ; Pierfrancesco LAPOLLA ; Andrea MINGOLI ; Alberto PORCU ; Nehal S. SHAH ; Zaed Z. R. HAMADY ; Bilal AL-SARRIEH ; Alejandro SERRABLO ; ; Somaiah AROORI
Annals of Hepato-Biliary-Pancreatic Surgery 2024;28(1):70-79
Background:
s/Aims: After pancreatoduodenectomy (PD), an early oral diet is recommended; however, the postoperative nutritional management of PD patients is known to be highly variable, with some centers still routinely providing parenteral nutrition (PN). Some patients who receive PN experience clinically significant complications, underscoring its judicious use. Using a large cohort, this study aimed to determine the proportion of PD patients who received postoperative nutritional support (NS), describe the nature of this support, and investigate whether receiving PN correlated with adverse perioperative outcomes.
Methods:
Data were extracted from the Recurrence After Whipple’s study, a retrospective multicenter study of PD outcomes.
Results:
In total, 1,323 patients (89%) had data on their postoperative NS status available. Of these, 45% received postoperative NS, which was “enteral only,” “parenteral only,” and “enteral and parenteral” in 44%, 35%, and 21% of cases, respectively. Body mass index < 18.5 kg/m2 (p = 0.03), absence of preoperative biliary stenting (p = 0.009), and serum albumin < 36 g/L (p = 0.009) all correlated with receiving postoperative NS. Among those who did not develop a serious postoperative complication, i.e., those who had a relatively uneventful recovery, 20% received PN.
Conclusions
A considerable number of patients who had an uneventful recovery received PN. PN is not without risk, and should be reserved for those who are unable to take an oral diet. PD patients should undergo pre- and postoperative assessment by nutrition professionals to ensure they are managed appropriately, and to optimize perioperative outcomes.
5.Do some patients receive unnecessary parenteral nutrition after pancreatoduodenectomy?Results from an international multicentre study
Thomas B. RUSSELL ; Peter L. LABIB ; Paula MURPHY ; Fabio AUSANIA ; Elizabeth PANDO ; Keith J. ROBERTS ; Ambareen KAUSAR ; Vasileios K. MAVROEIDIS ; Gabriele MARANGONI ; Sarah C. THOMASSET ; Adam E. FRAMPTON ; Pavlos LYKOUDIS ; Manuel MAGLIONE ; Nassir ALHABOOB ; Hassaan BARI ; Andrew M. SMITH ; Duncan SPALDING ; Parthi SRINIVASAN ; Brian R. DAVIDSON ; Ricky H. BHOGAL ; Daniel CROAGH ; Ismael DOMINGUEZ ; Rohan THAKKAR ; Dhanny GOMEZ ; Michael A. SILVA ; Pierfrancesco LAPOLLA ; Andrea MINGOLI ; Alberto PORCU ; Nehal S. SHAH ; Zaed Z. R. HAMADY ; Bilal AL-SARRIEH ; Alejandro SERRABLO ; ; Somaiah AROORI
Annals of Hepato-Biliary-Pancreatic Surgery 2024;28(1):70-79
Background:
s/Aims: After pancreatoduodenectomy (PD), an early oral diet is recommended; however, the postoperative nutritional management of PD patients is known to be highly variable, with some centers still routinely providing parenteral nutrition (PN). Some patients who receive PN experience clinically significant complications, underscoring its judicious use. Using a large cohort, this study aimed to determine the proportion of PD patients who received postoperative nutritional support (NS), describe the nature of this support, and investigate whether receiving PN correlated with adverse perioperative outcomes.
Methods:
Data were extracted from the Recurrence After Whipple’s study, a retrospective multicenter study of PD outcomes.
Results:
In total, 1,323 patients (89%) had data on their postoperative NS status available. Of these, 45% received postoperative NS, which was “enteral only,” “parenteral only,” and “enteral and parenteral” in 44%, 35%, and 21% of cases, respectively. Body mass index < 18.5 kg/m2 (p = 0.03), absence of preoperative biliary stenting (p = 0.009), and serum albumin < 36 g/L (p = 0.009) all correlated with receiving postoperative NS. Among those who did not develop a serious postoperative complication, i.e., those who had a relatively uneventful recovery, 20% received PN.
Conclusions
A considerable number of patients who had an uneventful recovery received PN. PN is not without risk, and should be reserved for those who are unable to take an oral diet. PD patients should undergo pre- and postoperative assessment by nutrition professionals to ensure they are managed appropriately, and to optimize perioperative outcomes.